Akari Therapeutics plc announced a business update highlighting progress made in 2025 and outlined its path toward becoming a clinical-stage oncology company in 2026. The company is advancing its proprietary PH1 spliceosome-modulating payload for antibody-drug conjugates (ADCs), designed to deliver both direct tumor cell cytotoxicity and immune activation. In 2025, Akari established a strategic manufacturing partnership with WuXi Biologics and initiated Chemistry, Manufacturing and Controls $(CMC)$ and other pre-filing activities to support clinical readiness. The company plans to start its first-in-human clinical trial as early as the end of 2026. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and has demonstrated significant activity and prolonged survival in preclinical studies, both as a single agent and in combination with checkpoint inhibitors. IND enabling studies for AKTX-101 are underway, and Akari is also advancing AKTX-102, an ADC targeting a novel antigen relevant in gastrointestinal and lung cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akari Therapeutics plc published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9622651-en) on January 09, 2026, and is solely responsible for the information contained therein.